Haibu Medicine has reached a strategic cooperation with InfiZhi Medicine.

On May 12, 2021, Beijing Haibu Pharmaceutical Technology Co., Ltd. and Beijing Yingfei Zhiyao Technology Co., Ltd. signed a strategic cooperation agreement.

Beijing Yingfei Zhiyao Technology Co., Ltd. has an independently owned AI + new drug research and development platform - PharmaMind (TM), which integrates multi-disciplinary experts, cutting-edge drug design methods, and precise big data systems. It includes globally leading practical core technologies such as 'system-based target discovery and combination analysis', 'prediction of potential drug resistance mutation sites for drug targets', 'structure-based druggability analysis of proteins', 'structure-based three-dimensional molecular generation', 'high-precision ultra-high-throughput virtual screening', 'optimization of high-drug-like lead compounds', 'de novo design and optimization for multiple targets', 'allosteric drugs/IDP drug design' and 'high-precision compound structure image recognition'. Yingfei Zhiyao is committed to promoting the development of new drug research pipelines that reflect the absolute advantages of AI technology, providing advanced solutions for unmet clinical needs.

Beijing Haibu Pharmaceutical Technology Co., Ltd. has rich successful experience in the research and development of small molecule chemical drugs. In recent years, Haibu Pharmaceutical has actively explored and achieved some results in areas such as compound design, structural modification, synthesis process route optimization, formulation technology improvement, and polymorph challenges for small molecule chemical innovative drugs. The Haibu team is well-versed in the laws, regulations, and technical guidelines related to small molecule chemical drug R&D, possessing efficient project management capabilities throughout the entire process from project evaluation, patent strategy design, preclinical research, clinical trial management, to drug registration until product qualification for market launch.

Both parties agree that AI drug discovery and design possess unique perspectives and new ideas for drug R&D. They can significantly reduce R&D costs, improve success rates in R&D, and accelerate the market launch of drugs. After this strategic cooperation is established, both parties will fully leverage their respective technological expertise, experience, and resource advantages to provide efficient solutions for the entire process from target discovery to commercial production of innovative drugs, promoting the accelerated market launch of small molecule chemical innovative drugs.

According to the agreement, both parties can carry out multi-faceted cooperation in various fields such as new target discovery for small molecule chemical innovative drugs, compound structure design and optimization, process route design and optimization, preclinical research, project management, registration approval processes, and commercial production to achieve collaborative innovation and jointly advance the development and market launch process of small molecule chemical innovative drugs.